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Substance Use Screening and 
Risk Assessment in Adults 
Purpose and Development of This Guideline 
This guideline on screening and risk assessment for substance use in adults (≥18 years old) was developed by the New 
York State (NYS) Department of Health (DOH) AIDS Institute (AI) for use by primary care providers and in other adult 
outpatient care settings in NYS to achieve the following goals: 
• Increase the identification of unhealthy substance use among NYS residents and increase access to evidence-based 
interventions for appropriate patients. “Unhealthy substance use” refers to a spectrum of use that increases the risk of 
health consequences and ranges from hazardous or risky patterns of use to severe substance use disorder (SUD). 
• Increase the number of clinicians in NYS who perform substance use screening and risk assessment as an integral part 
of primary care. 
• Provide clinicians with guidance on selecting validated substance use screening and risk assessment tools and on 
providing or referring for evidence-based interventions. 
• Promote a harm reduction approach to the identification and treatment of substance use and SUDs, which involves 
practical strategies and ideas aimed at reducing the negative consequences associated with substance use. 
­ See the NYSDOH AI guideline Harm Reduction Approach to Treatment of All Substance Use Disorders. 
Role of Primary Care Providers in New York State 
Primary care providers in NYS play an essential role in identifying and addressing unhealthy substance use in their 
patients. In light of the potential consequences of alcohol and drug use for individuals, communities, and healthcare 
systems, this committee recommends that all primary care providers in NYS be prepared to perform or provide substance 
use screening, assessment of risk level, and brief interventions as appropriate. 
Development of This Guideline 
This guideline was developed by the NYSDOH AI Clinical Guidelines Program, which is a collaborative effort of the NYSDOH 
AI Office of the Medical Director and the Johns Hopkins University School of Medicine, Division of Infectious Diseases. 
Established in 1986, the goal of the Clinical Guidelines Program is to develop and disseminate evidence-based, state-of-
the-art clinical practice guidelines to improve the quality of care throughout NYS for people who have HIV, hepatitis C 
virus, or sexually transmitted infections; people with substance use issues; and members of the LGBTQ community. 
NYSDOH AI guidelines are developed by committees of clinical experts through a consensus-driven process. 
The NYSDOH AI charged the Substance Use Disorder Guideline Committee with developing evidence-based clinical 
recommendations to guide primary care and other medical care providers in screening for substance use and assessing 
the level of risk in adult patients with unhealthy use. The resulting recommendations are based on extensive review of the 
medical literature and reflect consensus among the committee members. Each recommendation is rated for strength and 
quality of evidence based on the rating scheme below. If a recommendation is based on expert opinion, the rationale for 
the opinion is provided in the text. 
See About the Substance Use Disorder Guidelines for a full description of the development process, including evidence 
collection and recommendation development. 
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AIDS Institute Clinical Guidelines Program Recommendations Rating Scheme 
Strength of 
Recommendation 
Quality of Supporting Evidence 
A = Strong 1 = At least one randomized trial with clinical outcomes and/or validated laboratory 
endpoints 
B = Moderate 2 = One or more well-designed, nonrandomized trials or observational cohort studies with 
long-term clinical outcomes 
C = Optional 3 = Expert opinion 
Definition of Terms 
Screening 
Screening entails asking patients brief questions about substance use and should be routinely performed by care 
providers for all patients seen in medical settings. This guideline recommends substance use screening for all adults seen 
by primary care providers. Screening can quickly identify patients with potentially unhealthy substance use (see Box 1: 
Unhealthy Substance Use, below), many of whom will not have substance use–related clinical signs or symptoms [Gordon, 
et al. 2013; Saitz R., et al. 2014a]. Most screening instruments are brief and may be as short as a single question; 
therefore, they do not collect detailed information on the risk level, duration, or specific pattern of substance use. 
• See guideline section on Substance Use Screening for All Adult Patients in the Primary Care Setting 
• See Table 1: Recommended Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults 
Box 1: Unhealthy Substance Use 
• “Unhealthy substance use” refers to a spectrum of use that increases the risk of health consequences and ranges 
from hazardous or risky patterns of use to severe substance use disorder (SUD). 
• As defined here, unhealthy alcohol use is use that exceeds guideline-recommended levels; for illicit drugs, any use is 
considered potentially unhealthy. For prescription medications with potential for misuse, any nonmedical use (use 
of prescribed medication at increased dose or frequency or for reasons other than prescribed) or use of medications 
that were not prescribed is considered unhealthy. 
• Brief screening tools can identify potentially unhealthy use and can be followed by a risk assessment to determine 
the clinical significance and severity of use.   
Risk Assessment 
Risk assessment is performed using brief assessment tools to collect information on the extent, duration, and pattern of 
an individual patient’s substance use. Assessment tools determine the level of risk (i.e., low, moderate, or high) and thus 
the potential for negative consequences (see Box 2: Substance Use Levels of Risk, below). This guideline recommends that 
clinicians use only validated questionnaires for risk assessment in patients who have a positive screening result or a 
history of SUD or overdose (see guideline section on Risk Assessment). As shown in Figure 1: Substance Use Identification 
and Risk Assessment in Primary Care, below, risk level and other individual patient factors guide clinicians in 
recommending appropriate interventions and informing patients about the potential consequences of their substance use 
[Saitz R. 2005; McNeely J, et al. 2016b]. 
• See guideline section on Risk Assessment 
• See Table 2: Brief, Validated Risk Assessment Tools for Use in Medical Settings With Adults ≥18 Years Old 
• See guideline section on Diagnosis of Substance Use Disorder 
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Box 2: Substance Use Levels of Risk [a] 
• Low risk: Patient is abstinent or uses substances in a way that is not currently associated with negative health 
consequences or other problems (e.g., alcohol consumption that does not exceed guideline-recommended levels or 
occasional cannabis use). 
• Moderate risk: Patient is at risk for and may already be experiencing negative health consequences or other 
problems, such as elevated blood pressure related to alcohol use, atypical chest pain related to cocaine use, or 
family problems or poor work performance related to opioid use. 
• High risk: Patient likely has an SUD, is likely experiencing substance-related health or other types of problems (e.g., 
alcohol use–related cirrhosis or consequences such as separation from family or loss of employment), and is 
engaging in continued or escalating use despite negative consequences. 
a. Adapted from [Saitz R. 2005]. 
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Goals of Screening and Risk Assessment 
In the United States, tobacco, alcohol, and other (e.g., illicit, nonmedical prescription) drug use are among the top 10 
leading causes of preventable death, accounting for more than 500,000 deaths per year [GBDS 2018; White, et al. 2020]. 
Alcohol-related deaths have doubled in the past 2 decades; in 2017, there were more than 72,500 alcohol-related deaths 
in the United States [White, et al. 2020]. Increases in opioid use disorder and skyrocketing rates of drug overdose deaths 
(often opioid-related) are a public health crisis across the country [DHHS 2016; Rudd, et al. 2016; Dowell, et al. 2017; 
Wilson, et al. 2020]. 
Patient visits to healthcare settings are an opportunity for clinicians to identify substance use and related problems, offer 
timely interventions, and provide or link patients to treatment when indicated. Screening and treatment for tobacco use 
have been widely adopted as core clinical quality measures for primary care [CMS 2013], but alcohol and drug use 
screening is not as widely performed, and use is substantially under-recognized [Venkatesh and Davis 2000; WHO 2016]. 
Although screening for alcohol use has been a recommended practice in adult primary care since 1996 [Curry, et al. 2018], 
only 1 in 6 adults in the United States report ever discussing alcohol use with a healthcare professional [McKnight-Eily, et 
al. 2014]. 
Screening for substance use in primary care is generally well accepted by patients as a marker of quality care [Miller, et al. 
2006; Simonetti, et al. 2015]. However, for patients and care providers to be comfortable, thoughtful implementation, 
with sensitivity to stigma and privacy concerns, is essential [McNeely J, et al. 2018; Bradley, et al. 2020] (see the NYSDOH 
AI guideline Harm Reduction Approach to Treatment of All Substance Use Disorders > Reducing Stigma). 
The goals of screening for and assessing substance use in primary care vary by practice setting and resources and may 
include: 
• Informing medical care: One goal is to inform a patient’s medical care. Substance use is an important aspect of medical 
history because it can significantly affect disease processes, response to treatment, and exposure to health risks. 
Knowledge of a patient’s substance use informs a care provider’s diagnosis of other medical and psychiatric conditions 
and alerts them to associated health risks (e.g., overdose, liver disease) and common comorbid conditions (e.g., 
depression). Similar to knowing about a patient’s past medical history, family history, or social determinants of health, 
knowing about a patient’s substance use helps care providers formulate effective patient-centered treatment plans. 
• Identifying the need for intervention: A second goal is to identify patients who would benefit from interventions to 
reduce their consumption (see guideline section on Management of Low-, Moderate-, and High-Risk Substance Use) or 
patients who are candidates for substance use disorder treatment (see Figure 1: Substance Use Identification and Risk 
Assessment in Primary Care). Evidence-based interventions are available, including brief interventions for moderate-
risk alcohol use, pharmacotherapy for opioid and alcohol use disorders, and treatment for smoking cessation [USPHS 
2008; Jonas, et al. 2014; Mattick, et al. 2014; Curry, et al. 2018; Patnode, et al. 2020]. Such treatments can be delivered 
effectively in a primary care setting, but they remain underused. 
­ See the NYSDOH AI guidelines Treatment of Opioid Use Disorder and Treatment of Alcohol Use Disorder. 
• Engaging patients: Another goal is opening the conversation and engaging patients in discussion about substance use; 
if done with knowledge and sensitivity, this may reduce stigma, improve the patient–care provider relationship, and 
lead to behavior change. Initiating a discussion about substance use communicates to patients that it is a health issue, 
not a moral failing, and that their care provider is concerned enough about substance use to address it and offer help 
(see the NYSDOH AI guideline Harm Reduction Approach for Treatment of All Substance Use Disorders > Reducing 
Stigma). 
→ KEY POINT 
• It is essential that clinicians are aware of their own biases and try to set them aside when screening and evaluating 
patients for drug and alcohol use; see the NYSDOH AI guideline Harm Reduction Approach for Treatment of All 
Substance Use Disorders > Reducing Stigma. 
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Substance Use Screening for All Adult Patients in the Primary 
Care Setting 
 RECOMMENDATIONS 
Primary Care Screening for Adults 
• During the initial visit and during annual follow-up visits, primary care clinicians should screen for the following in 
adults ≥18 years old: 
­ Alcohol use, and when unhealthy use is identified, assess the level of risk to the patient. (A1) 
­ Tobacco use, and when it is identified, provide assessment and counseling. (A1) 
­ Drug use (B3), and when unhealthy use is identified, assess the level of risk to the patient. (A3)  
o See guideline section on Risk Assessment 
• Before screening for drug use, clinicians should explain the risks and benefits of screening to all patients, especially 
those who are pregnant or planning to conceive; the discussion should include state reporting requirements and the 
potential for involvement of child protective services. (A3) 
­ For information on the Child Abuse Prevention and Treatment Act (CAPTA) in New York State, see Plans of Safe 
Care for Infants and their Caregivers. 
• Clinicians should repeat substance use screening to inform clinical care when: 
­ Prescribing medication(s) that have adverse interactions with alcohol or drugs. (A2) 
­ A patient has symptoms or medical conditions that could be caused or exacerbated by substance use. (A3) 
 
→ KEY POINTS 
• It is important to ask patients about substance use during an initial visit and during follow-up visits because patterns 
of use may change over time. Annual screening may be most appropriate, and most validated alcohol and drug 
screening questionnaires ask about use in the past year. 
• It is important to inform patients that information about their substance use is protected by the same privacy laws 
that apply to all other information in their medical records. 
Alcohol 
In primary care settings, clinicians should screen all adult patients ≥18 years old for alcohol use. A large body of evidence 
indicates that screening tools can accurately identify unhealthy alcohol use (see Table 1: Recommended Validated Tools 
for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults) and that brief counseling interventions can 
reduce alcohol use, improve health, and be cost-effective [Maciosek, et al. 2006; McNeely JD, et al. 2008; Solberg, et al. 
2008; Kaner, et al. 2009; O'Donnell, et al. 2014; O'Connor, et al. 2018; Patnode, et al. 2020]. The National Committee on 
Quality Assurance adopted alcohol screening and brief intervention as a quality indicator in 2018 and incorporated it into 
the widely used Healthcare Effectiveness Data and Information Set (HEDIS) performance measures.  
In the absence of systematic screening, unhealthy alcohol use typically goes unidentified [McKnight-Eily, et al. 2017] or is 
identified by healthcare providers only when an individual has developed a severe alcohol use disorder or alcohol-related 
health problems, such as alcohol-related cirrhosis or pancreatitis. In a study among individuals reporting current alcohol 
use, only 17.4% reported ever discussing their use with a health professional, and the rate was only modestly higher 
(25.4%) for those who reported binge drinking [McKnight-Eily, et al. 2017]. 
Tobacco 
Clinicians should screen all patients for all types of tobacco use, and when it is identified, provide counseling, assessment, 
and treatment [USPHS 2008]. Every visit with a healthcare provider affords the opportunity to identify a patient’s tobacco 
use and offer effective cessation interventions. Screening for tobacco use is often accomplished with 1 question: “Have 
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you ever smoked cigarettes or used any other kind of tobacco?” Patients who answer “yes” should be asked about 
frequency and level of use in the past 30 days (e.g., number of cigarettes smoked per day) [AHRQ 2014]. Despite concern 
about increasing rates of e-cigarette use, screening for electronic nicotine delivery systems is not currently a 
recommended practice [USPSTF 2020]. 
Drugs 
Based on clinical experience and expertise, this committee recommends that clinicians screen for drug use in adult 
patients ≥18 years old who present for primary care. The decision to screen should consider the rationale and specific 
circumstances discussed below and should only be performed for the purpose of informing clinical care. Screening should 
identify a patient’s use of illicit drugs and nonmedical use of prescription drugs that can be misused (e.g., opioids, 
benzodiazepines, and stimulants). 
Evidence supports the accuracy of validated screening questionnaires in adults [Patnode, et al. 2020]; however, data on 
the effectiveness of drug screening plus brief intervention to reduce drug use and associated health consequences are 
currently limited, and this is an area of active research. Randomized controlled clinical trials have generated mixed results 
regarding the efficacy of brief interventions in reducing drug use [Humeniuk, et al. 2012; Roy-Byrne, et al. 2014; Saitz R., 
et al. 2014b; Gelberg, et al. 2015; Patnode, et al. 2020]. 
Evidence supports the benefits of pharmacologic treatment for opioid use disorder, which can be delivered effectively in 
primary care settings (see the NYSDOH guideline Treatment of Opioid Use Disorder > Treatment Options). However, no 
pharmacotherapy is currently approved by the U. S. Food and Drug Administration for other types of drug use disorders. 
Some patients with unhealthy use of drugs other than opioids will benefit from referral to addiction treatment or from 
psychosocial interventions integrated into primary care, but data on long-term outcomes of interventions in primary care 
settings are scarce, and many patients may not have access to evidence-based services [Chou, et al. 2019]. 
No currently published studies demonstrate harms associated with screening adult primary care patients for drug use, 
although the potential for harm does exist [Saitz R 2020]. For some patients, especially those who are pregnant or 
planning to conceive, positive results from a drug screening test could pose social or legal consequences, such as required 
reporting and the potential for involvement of child protective services (see discussion below). It is essential that care 
providers respect the sensitivity of any substance use information documented in patients’ health records and ensure that 
patients understand privacy protections for their health information. 
Rationale for screening: This committee’s rationale for recommending drug use screening in adult patients, even with the 
potential for harm in some specific circumstances, is based on the following: 
• Stigma is a significant barrier to identifying and treating unhealthy drug use or substance use disorders (SUDs). The 
exclusion of routine screening for drug use may perpetuate the perception that discussion of drug use with healthcare 
providers is taboo. This is especially the case if alcohol and tobacco use are discussed openly but drug use is not 
mentioned. Routine, matter-of-fact, nonjudgmental screening for drug use may help reduce stigma by normalizing this 
discussion. 
• The social history that clinicians currently perform typically includes questions about alcohol, tobacco, and drug use but 
may not collect this information in a systematic and clinically useful manner. It is important that clinicians screen for 
drug use consistently, in a nonbiased manner, and use standardized, evidence-based screening tools. 
• Opioid overdose deaths can be reduced through increased identification of unhealthy opioid use and, when indicated, 
effective treatment with medications for opioid use disorder [Cousins, et al. 2016; Sordo, et al. 2017; SAMHSA 2019]. 
• Identifying and addressing unhealthy drug use, including drug use disorders, may positively affect other patient 
outcomes. For instance, identification of nonmedical benzodiazepine use in a patient receiving opioids for chronic pain 
could inform overdose prevention counseling, opioid prescribing, and provision of naloxone to reduce the patient’s 
overdose risk. 
• Knowledge of a patient’s drug use is essential for accurate diagnosis and treatment. For example, in a patient who uses 
cocaine, chest pain could be the result of drug use rather than a blocked coronary artery, but without knowledge of the 
drug use, the healthcare provider will not have the information necessary to perform the appropriate diagnostic work-
up. In addition, knowledge of drug use may be essential for an accurate diagnosis of psychiatric disorders, and 
knowledge of injection drug use can help guide screening for infections. 
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→ KEY POINT 
• Urine toxicology, measures of blood alcohol level, and other laboratory tests should not be relied on for identifying 
unhealthy drug use. 
Screening in individuals who are pregnant or planning to conceive: Because there are potential legal and social 
consequences of a positive drug use screening result in individuals who are pregnant or planning to conceive, this 
committee urges caution when performing drug use screening. It is essential to engage patients in shared and informed 
decision-making before screening is performed. Fully informed consent includes clear discussion and confirmed patient 
understanding of the potential harms, consequences, and benefits of screening. For patients who are pregnant or 
planning to conceive, the informed consent discussion should include: 
• Description of drug screening processes and procedures. 
• Potential benefits of drug screening for the patient. 
• Discussion of how results are interpreted and likely next steps if the screening result is positive. 
• Confirmation of confidentiality of the patient’s medical information. 
• Description of the CAPTA law and legal requirements for healthcare providers when screening results are positive. 
• Discussion of the patient’s ability to refuse drug screening without repercussions, except in cases in which screening is 
mandated by an employer or by the court. 
• Psychosocial support and counseling about potential harms of drugs and treatment options for SUD, if patients decline 
to be screened for other drugs. 
Repeat screening to inform clinical care in individual patient circumstances: Iatrogenic harm is possible if a patient’s 
drug use is not identified, including adverse effects resulting from drug-medication interactions, overdose from combining 
prescribed medications with illicit drugs, and withdrawal syndromes when a patient’s drug use is undisclosed and they are 
unable to use, such as during hospitalization [Antoniou and Tseng 2002; CDC 2007; Lindsey, et al. 2012]. 
Clinicians should repeat substance use screening in patients who have symptoms or other medical conditions that could 
be caused or exacerbated by substance use, such as chest pain, liver disease, or mood disorders [Lock and Kaner 2004; 
Mertens, et al. 2005; Ries, et al. 2014; Edelman and Fiellin 2016; Kim, et al. 2016; NIAAA 2016]. 
Screening is also recommended for patients who use medications that have adverse interactions with alcohol or drugs 
and for patients who engage in known risk behaviors, such as unprotected sex, that may co-occur with substance use 
[Rehm, et al. 2012; Scott-Sheldon, et al. 2016; McKetin, et al. 2018; Maxwell, et al. 2019]. Patients taking prescription 
opioids or benzodiazepines should be screened for use of alcohol and for illicit or nonmedical use of other sedating drugs 
(including other opioids or benzodiazepines) that can increase the risk of overdose. Patients taking any controlled 
substances should be assessed for co-occurring substance use that may increase the probability of engaging in risky use of 
prescribed medications or of having or developing an SUD. Specific assessment tools (e.g., Opioid Risk Tool, Current Opioid 
Misuse Measure) have been developed to predict and evaluate prescription opioid misuse among patients receiving 
chronic opioid therapy, but discussion of these tools is beyond the scope of this guideline. Care providers should be aware 
of potential interactions between alcohol or drugs and medications, such as antiretroviral, pain management, or 
neurologic medications (e.g., gabapentin and pregabalin) [Antoniou and Tseng 2002; Saitz R. 2005; Bruce, et al. 2008; 
Lindsey, et al. 2012; Gomes, et al. 2017; Lyndon, et al. 2017]. When counseling patients who use substances about drug-
medication interactions, care providers should be clear about the safety of their prescribed medications and be certain to 
encourage adherence to all critical medications, such as antiretroviral treatment [Kalichman, et al. 2015]. 
See the following resources for checking drug interactions: 
• Drugs.com > Drug Interactions Checker 
• University of Liverpool HEP Drug Interactions Checker 
• University of Liverpool HIV Drug Interactions Checker 
• Consensus validation of the POSAMINO (POtentially Serious Alcohol–Medication INteractions in Older adults) criteria 
[Holton, et al. 2017] 
• NYSDOH AI ART Drug-Drug Interactions  
• For patients: National Institute on Alcohol Abuse and Alcoholism > Harmful Interactions: Mixing Alcohol With Medicines 
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Implementing Substance Use Screening in Primary Care Settings 
• Who to screen: All adults seen by primary care providers should be screened for substance use. Some specific 
patient populations may have higher rates of unhealthy substance use [Schulden, et al. 2009; SAMHSA 2019], but 
there are no specific demographic characteristics that reliably predict such use. 
• How often to screen: Because substance use behavior changes over time, care providers should repeat screening at 
regular intervals. However, evidence is lacking about the optimal frequency of screening [Moyer 2013]. Annual 
screening may strike the best balance between the need for frequent repetition of screening and time and resource 
constraints and has been recommended by an expert panel convened by the National Council for Behavioral Health 
and Substance Abuse and Mental Health Services Administration (SBIRT Change Guide, February 2018) [SAMHSA 
2018]. 
• Who should perform the screening: Most of the screening instruments discussed in Table 1: Recommended 
Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults can be administered verbally 
by trained staff or can be self-administered by patients on paper or on a computer. Primary care practices must 
choose the format that is most appropriate for their clinical workflow and patient population. Generally, self-
administered screening facilitates more accurate reporting of stigmatized behavior, such as substance use 
[Tourangeau and Smith 1996; Wight, et al. 2000]. A self-administered approach may ensure fidelity of administration 
[Bradley, et al. 2011; Williams, et al. 2015], increase patient comfort [Spear, et al. 2016; McNeely J, et al. 2018], and 
reduce the burden on staff. Electronic screening tools that can be self-administered can be completed online 
through a patient portal or an app made available with a tablet computer or kiosk in the clinic, with results uploaded 
to a patient’s electronic health record. 
• How to introduce substance use screening to patients: Explain the reasons for screening, the type of screening that 
will be performed, the potential benefits, and any potential harms. Make sure that patients understand how results 
will be interpreted and the likely response to screening results. Remind them of the privacy protections for the 
information being collected, including who will see the information; acknowledge the potential sensitivity of the 




• Healthcare providers should use standardized and validated questionnaires for substance use screening (see Table 1: 
Recommended Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults). (A3) 
Successful substance use screening relies on accurate patient self-report. Although urine toxicology, measures of blood 
alcohol level, or other laboratory testing may detect the presence of substances used very recently, (typically hours or ≤4 
days after the last use), these tests are not appropriate for identifying unhealthy use, which may be intermittent and 
occur over time [Verstraete 2004; Cone and Huestis 2007; Bosker and Huestis 2009]. Laboratory screening tests for 
alcohol and drugs do not provide information about the severity or consequences of use, and thus provide less 
information than questionnaires.   
There is no reliable biomarker with sufficient sensitivity and specificity to identify the range of drinking behaviors that 
constitute unhealthy alcohol use [Neumann and Spies 2003; Verstraete 2004; Jatlow, et al. 2014; Stewart, et al. 2014; 
Afshar, et al. 2017; Jarvis, et al. 2017]. For drug use, urine, saliva, and blood testing are not recommended as 
replacements for questionnaire-based screening because laboratory tests have a brief window of detection (typically 1 to 
4 days) [Verstraete 2004; Cone and Huestis 2007; Bosker and Huestis 2009]. Although hair testing has a more extended 
detection period, the cost and lack of reliability for detecting occasional drug use decrease its utility in primary care 
[Verstraete 2004]. 
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Table 1: Recommended Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults 
Tool [a], References Substance(s) Included No. of Items, Approximate Time 
Required to Complete, and Format 
AUDIT-C (Alcohol Use Disorders 
Identification Test–Concise) 
[Bush, et al. 1998; Bradley, et al. 2007] 
• Available in languages other than 
English 
Alcohol • 3 items; 1 to 2 minutes 
• Interviewer or self-administered via 
electronic app or on paper 
SISQ-Alc (Single-Item Screening Questions 
for Alcohol) 
[Smith, et al. 2009; McNeely J, et al. 
2015a] 
Alcohol • 1 item; 1 minute 
• Interviewer or self-administered via 
electronic app or on paper 
SISQ-Drug (Single-Item Screening 
Questions for Drug Use) 
[Smith, et al. 2010; McNeely J, et al. 
2015a] 
Prescription drugs, other 
drugs 
• 1 item; 1 minute 
• Interviewer- or self-administered via 
electronic app or on paper 
SoDU (Screen of Drug Use) 
[Tiet, et al. 2015] 
Prescription drugs, other 
drugs 
• 2 items; 1 minute 
• Interviewer 
SUBS (Substance Use Brief Screen)  
[McNeely J and Saitz 2015] 
Tobacco, alcohol, prescription 
drugs, other drugs 
• 4 items; 2 minutes 
• Interviewer or self-administered via 
electronic app or on paper 
TAPS-1 (Tobacco, Alcohol, Prescription 
Medication, and Other Substance Use)  
[Gryczynski, et al. 2017] 
Tobacco, alcohol, prescription 
drugs, other drugs 
• 4 items; 2 minutes 
• Interviewer or self-administered via 
electronic app 
a. For information on the sensitivity and specificity of tools for drug screening, please see the U.S. Preventive Services Task Force 
(USPSTF) evidence review Unhealthy Drug Use: Screening; for information on the sensitivity and specificity for alcohol screening, see 
Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: An Updated 
Systematic Review for the USPSTF. 
 
→ KEY POINT 
• Whenever possible, it is best to have patients self-administer the screening and assessment questionnaires rather 
than having the clinician or staff ask the questions. In general, self-administered screening facilitates more accurate 
reporting of stigmatized behavior, such as substance use [Tourangeau and Smith 1996; Wight, et al. 2000; Bradley, 
et al. 2011; Williams, et al. 2015; Spear, et al. 2016; McNeely J, et al. 2018]. 
An optimal screening instrument will quickly and accurately identify individuals with the full spectrum of unhealthy use, fit 
into the existing clinical workflow, and have flexible administration options (i.e., self- or interviewer-administered). To 
facilitate patient report of substance use, the language used in any screening tool should be clear and nonjudgmental. 
Drug screening should capture nonmedical prescription drug use and illicit drug use. Table 1: Recommended Validated 
Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults, above, lists recommended substance use 
screening tools. 
The briefest approach to screening may be to use the Single-Item Screening Questions (SISQ) for alcohol or drug use 
(SISQ-Alc and -Drug). SISQ tools are validated for interviewer administration or self-administration and have good 
sensitivity and specificity. A positive response on SISQ tools identifies unhealthy use in the past year but does not indicate 
the level of risk. Both the Substance Use Brief Screen (SUBS) and the first section of the Tobacco, Alcohol, Prescription 
Medication, and Other Substance Use (TAPS-1) tool elicit information about use of tobacco, alcohol, illicit drugs, and 
nonmedical prescription drugs through a single 4-item instrument. Like the SISQ-Alc and -Drug, the SUBS and TAPS-1 tools 
screen for any use in the past year, and a positive response indicates unhealthy use but does not identify level of risk. 
In some circumstances, the purpose of screening may be to diagnose substance use disorder rather than identify 
unhealthy drug use. For example, if the clinical setting cannot offer early intervention or preventive care, screening may 
be used to identify individuals in need of referral to addiction treatment. In such cases, the Screen of Drug Use (SoDU) 
tool, which specifically identifies drug use disorders, may be used. The SoDU was validated using Diagnostic and Statistical 
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Manual of Mental Disorders–IV (DSM-IV) criteria, and a positive screen corresponds to a DSM-IV diagnosis of “drug abuse 
or dependence.”    
Alcohol: The briefest alcohol screening questionnaires (SISQ-Alc, TAPS-1, SUBS) use a single question about binge drinking 
in the past year to identify unhealthy alcohol use. Although it is possible for patients to use more alcohol than the 
recommended limits in the U.S. Department of Health and Human Services and Department of Agriculture Dietary 
Guidelines (14 drinks/week for men ≤65 years old, 7 drinks/week for women and men ≥65 years old), even in the absence 
of binge drinking, validation studies have demonstrated good sensitivity [NIAAA 2016; DHHS 2020]. The 3-item Alcohol 
Use Disorders Identification Test–Concise (AUDIT-C) is a widely used and recommended brief screening tool for alcohol 
use in medical settings [Bush, et al. 1998; Bradley, et al. 2003; Bradley, et al. 2007; Reinert and Allen 2007; Frank, et al. 
2008; Moyer 2013]. Unlike the other brief screening tools, the AUDIT-C identifies the level of risk to patients with problem 
use and high-risk use. The AUDIT-C does not screen for tobacco or drugs. 
Tobacco: Tobacco use is incorporated into some of the brief screening instruments (SUBS, TAPS-1) included in Table 1: 
Recommended Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults, above. The 
accuracy of SUBS and TAPS-1 tools for identifying tobacco use is high, with a sensitivity of 98% and a specificity ranging 
from 80% to 96% [McNeely J, et al. 2015b; Gryczynski, et al. 2017]. Use of a single instrument that concurrently screens 
for tobacco and alcohol use will streamline the screening process. 
Drugs: Screening for drug use can be performed with the SISQ-Drug, SUBS, or TAPS-1 tools, all of which perform well in 
validation studies of adults in primary care settings [McNeely J, et al. 2015a; McNeely J, et al. 2015b; McNeely J, et al. 
2016b; Gryczynski, et al. 2017]. With changes in the legal status of cannabis and shifting attitudes toward cannabis use, 
clinics should provide patients and staff with clear instructions about reporting cannabis use on questionnaires that 
categorize cannabis as an illicit drug [Lapham, et al. 2017]. In states where cannabis is legal, it may be best to ask about its 




• Clinicians should assess the level of substance use risk in individuals who have a positive substance use screening 
result or a history of substance use disorder (SUD) or overdose. (A3) 
• Clinicians should use standardized and validated tools to assess the level of risk associated with substance use (see 
Table 2: Brief, Validated Risk Assessment Tools for Use in Medical Settings With Adults ≥18 Years Old). (A3) 
Candidates for Risk Assessment 
Clinicians should use validated tools to perform substance use assessment in individual patients who have any of the 
characteristics discussed below. The purpose of assessment is to identify the level of risk (low, moderate, or high) posed 
by a patient’s substance use to guide clinical decisions about intervention, treatment, and follow-up (see Figure 1: 
Substance Use Identification and Risk Assessment in Primary Care). 
Positive substance use screening test: Given current levels of substance use in the general population and the negative 
effects of unhealthy substance use, any positive screening test result should prompt an efficient and accurate risk 
assessment [McNeely J, et al. 2015a; McNeely J, et al. 2015b]. 
Known history of SUD or overdose: Polysubstance use is common in people with SUD [Earleywine and Newcomb 1997; 
McLellan, et al. 2000; Falk, et al. 2006; Callaghan, et al. 2018]. For patients with a history of SUD, identification of all 
substances used, including tobacco, and assessment of the associated levels of risk are indicated for early intervention 
and clinical decision-making. SUDs are chronic conditions, and even patients with long periods of abstinence remain 
vulnerable to resuming previous patterns of use [McLellan, et al. 2000]. Patients with a history of SUD may reduce or stop 
use of one substance but develop unhealthy use of a different substance (e.g., alcohol) [Earleywine and Newcomb 1997; 
Falk, et al. 2006; Wang, et al. 2017; Callaghan, et al. 2018; Lin, et al.]. Furthermore, overdose is frequently the result of 
polysubstance use, often involving use of opioids in combination with alcohol and other drugs [Tori, et al. 2020]. In 
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patients with a history of nonfatal overdose, it is critically important to conduct an assessment and identify all of the 
substances being used; the results will guide education and treatment to reduce the risk of another overdose. 
The level of risk of associated with substance use in individuals who are planning to become pregnant should inform 
counseling, particularly in light of the risk of fetal alcohol spectrum disorder that occurs early in pregnancy [CDC 2003; 
DHHS 2005; Floyd, et al. 2006; Floyd, et al. 2008; Stade, et al. 2009; Moyer 2013; May, et al. 2018]. In addition, it is 
reasonable to perform a substance use assessment in patients with chronic diseases who have poor adherence to 
treatment recommendations or are not responding as expected to treatment of their medical condition [Daskalopoulou, 
et al. 2014; Garin, et al. 2017]. 
Risk Assessment Tools 
Substance use assessment tools are designed to collect information on the quantity, frequency, and duration of substance 
use and to indicate a risk level (see Table 2, below). 
Table 2: Brief, Validated Risk Assessment Tools for Use in Medical Settings With Adults ≥18 Years Old [a] 
Tool [a], References Substance(s) Included No. of Items, Approximate Time 
Required to Complete, and Format 
ASSIST (Alcohol, Smoking, and 
Substance Involvement Screening 
Test)  
[Humeniuk, et al. 2008] 
• Available in languages other than 
English 
Tobacco, alcohol, prescription drugs, 
other drugs; identifies specific drug 
classes 
• 10 to 71 items; 5 to 15 minutes, 
depending on no. of substances 
used 
• Interviewer administered 
ACASI-ASSIST (Audio Computer-
Assisted Self-Interview–ASSIST)  
[Kumar, et al. 2016; McNeely J, et al. 
2016a] 
Tobacco, alcohol, prescription drugs, 
other drugs; identifies specific drug 
classes 
• 10 to 98 items; 5 to 15 minutes, 
depending on no. of substances 
used 
• Self-administered on 
computer/tablet 
AUDIT (Alcohol Use Disorders 
Identification Test)  
[Reinert and Allen 2007] 
• Available in languages other than 
English 
Alcohol • 10 items; 3 minutes 
• Interviewer- or self-administered 
DUDIT (Drug Disorders Identification 
Test)  
[Berman AH, et al. 2003; Hildebrand 
2015] 
• Available in languages other than 
English 
All drugs; does not identify drug 
classes 
• 11 items; 5 minutes 
• Interviewer or self-administered on 
paper 
DAST-10 (Drug Abuse Screening 
Test)  
[Skinner 1982; Yudko, et al. 2007] 
• Available in languages other than 
English 
All drugs; does not identify drug 
classes 
• 10 items; 10 minutes or less 
• Interviewer or self-administered on 
paper 
TAPS (Tobacco, Alcohol, Prescription 
Medication, and Other Substance 
Use)  
[McNeely J, et al. 2016b; Adam, et 
al. 2019] 
Tobacco, alcohol, prescription drugs, 
other drugs; identifies specific drug 
classes 
• 4 to 25 items; 2 to 4 minutes, 
depending on no. of substances 
used 
• Interviewer or self-administered on 
computer/tablet 
a. Clinicians with experience in treating patients with substance use and substance use disorder may choose to use Diagnostic and 
Statistical Manual of Mental Disorders–5 diagnostic criteria as the initial assessment tool. 
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Alcohol use: To assess level of risk in patients who use alcohol, clinicians can use the Alcohol Use Disorders Identification 
Test (AUDIT) or the AUDIT-Concise (AUDIT-C) tool, both of which have been widely adopted in medical settings [Bradley, 
et al. 2003; NIAAA 2005; Bradley, et al. 2007; Reinert and Allen 2007]. The AUDIT is a 10-item questionnaire developed by 
the World Health Organization (WHO) for alcohol use screening in medical settings. The AUDIT-C consists of the first 3 
items of the AUDIT, which asks only about alcohol consumption. Although the full AUDIT is still widely used, the 3-item 
AUDIT-C performs as well as the full 10-item AUDIT instrument for identifying risky use and problem use in studies 
conducted among primary care patients in the United States [Bradley, et al. 2007]. However, use of the full AUDIT 
provides expanded information about problems related to alcohol use that may be helpful for care providers offering 
brief interventions or other alcohol counseling. 
Tobacco use: For patients who use tobacco, assessment of health risks is typically accomplished by asking about the 
number of cigarettes smoked per day. The 2-item Heaviness of Smoking Index, which asks about total cigarettes per day 
and the timing of the first cigarette, can determine the level of dependence for daily smokers. 
Drug use: For assessment of drug use, which can involve multiple substance classes with varying levels of risk, the 
instruments are by necessity more complex. The WHO Alcohol, Smoking, and Substance Involvement Screening Test 
(ASSIST) was one of the first screening tools designed for use in healthcare settings to provide substance-specific risk 
stratification for drugs. Its length and complexity have hindered its implementation in primary care settings [Babor, et al. 
2007; Ali, et al. 2013], but a self-administered electronic version may be more feasible [McNeely, et al. 2016a]. 
The more recently developed Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool 
streamlines the ASSIST to perform this assessment relatively quickly and still supply substance-specific information about 
the level of risk. Scores range from 0 to 4, with higher scores indicating greater severity. The TAPS tool was specifically 
developed for adult primary care and is recommended for use in general medical settings to screen for opioid and other 
substance use [SAMHSA 2018a]. It is validated in an electronic, patient self-administered format (myTAPS) [Adam, et al. 
2019] and a more traditional interviewer-administered questionnaire. An online version of the TAPS tool with clinical 
guidance on interpreting the scores and resources for intervention is available on the National Institute on Drug Abuse 
TAPS website. 
Management of Low-, Moderate-, and High-Risk Substance 
Use 
Lead authors: Susan D. Whitley, MD, 2 and Alan Rodriguez Penney, MD, 3 with the Substance Use Disorder Guideline 
Committee, October 2020 
Assessment with validated tools can characterize the level of risk as low, moderate, or high (see Figure 1: Substance Use 
Identification and Risk Assessment in Primary Care and Table 2: Brief, Validated Risk Assessment Tools for Use in Medical 
Settings With Adults ≥18 Years Old). Intervention options for substance use are determined by the level of risk identified 
in the assessment process, an individual’s perception of the problem, and time restrictions, among other factors. 
Individuals with unhealthy substance use regularly interact with the healthcare system, and primary care settings are 
optimally positioned to offer prevention and treatment interventions. All clinicians can develop the skills to offer 
treatment or refer patients for appropriate interventions [Edelman and Fiellin 2016; McLellan 2017]. 
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Harm reduction strategies should be discussed with individuals who engage in substance use at all risk levels; see the 
NYSDOH AI guideline Harm Reduction Approach to Treatment of All Substance Use Disorders > Box 2: Harm Reduction 
Counseling in the Medical Setting. 
Clinical resources for addressing tobacco use include the New York State Department of Health Information about 
Tobacco Use, Smoking and Secondhand Smoke, the New York City Department of Health and Mental Hygiene publication 
Treating Tobacco Addiction, and the American Academy of Family Physicians table of FDA-Approved Medications for 
Smoking Cessation. For patients who use any type of tobacco, the U.S. Public Health Service Clinical Practice Guideline for 
Treating Tobacco Use and Dependence: 2008 Update recommends the “5 As” approach as an intervention: 
1. Ask patients about tobacco use. 
2. Advise tobacco users to quit. 
3. Assess willingness to quit. 
4. Assist in a quit attempt. 
5. Arrange for follow-up. 
For individuals with low-risk use of any substance, clinicians can offer positive reinforcement and reminders of the 
negative consequences of use. For individuals who use alcohol, clinicians can provide information on the recommended 
limits of use; see the U.S. Department of Health and Human Services and Department of Agriculture Dietary Guidelines 
[DHHS 2020]. Robust evidence supports the efficacy of screening and brief interventions in the primary care setting for 
reducing alcohol use among individuals with unhealthy use who do not meet criteria for alcohol use disorder [Jonas, et al. 
2012; Curry, et al. 2018]. Studies on the efficacy of brief interventions in reducing drug use have found mixed results 
[Humeniuk, et al. 2012; Roy-Byrne, et al. 2014; Saitz R., et al. 2014b; Gelberg, et al. 2015]; however, brief interventions 
are recommended by the Substance Abuse and Mental Health Services Administration and have been implemented in 
many healthcare settings with no evidence of harm [SAMHSA 2018]. If an individual has high-risk substance use, it is 
essential to perform or refer for a full diagnostic substance use disorder assessment using the Diagnostic and Statistical 
Manual of Mental Disorders–5 criteria (see guideline section on Diagnosis of Substance Use Disorder). 
Brief interventions: Brief interventions range from 5 to 20 minutes in duration, vary in frequency, and include a variety of 
components based on different psychological and motivational approaches. Common elements of a brief intervention 
include discussion of the risks and benefits of substance use as perceived by the patient, individualized feedback 
regarding level of risk, advice on reducing use to within recommended safe limits, discussion of any related health effects, 
and motivational support (see Figure 2: Brief Intervention: “Can We Spend a Few Minutes Talking About Your Substance 
Use?”, below). A commonly used acronym is FRAMES: Feedback, Responsibility, Advice, Menu Options, Empathy, and Self-
Efficacy. The time available for an intervention and the individual’s level of engagement and motivation for change often 
determine the duration, type, and frequency of brief interventions. 
For further information and resources, see the NYSDOH AI guideline Treatment of Alcohol Use Disorder > Non-
Pharmacological Treatment > Online Resources: Behavioral Therapy for Alcohol Use Disorder. 
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Diagnosis of Substance Use Disorder 
Lead authors: Susan D. Whitley, MD, 4 and Alan Rodriguez Penney, MD, 5 with the Substance Use Disorder Guideline 
Committee, October 2020 
 RECOMMENDATIONS 
Diagnosis of Substance Use Disorder 
• For accurate diagnosis of a substance use disorder (SUD) and its severity, clinicians should perform or refer patients 
for a full assessment based on Diagnostic and Statistical Manual of Mental Disorders–5 (DSM-5) criteria. (A3) 
• Clinicians should assess patients’ perceptions of their substance use and readiness to change substance use 
behaviors. (A3) 
• If individuals present with symptoms consistent with both an SUD and a mental health disorder, clinicians should 
assess for both types of disorder before making a diagnosis and should refer for specialty behavioral healthcare 
when indicated. (A3) 
Healthcare providers should perform or refer patients for a full assessment based on DSM-5 diagnostic criteria to 
accurately diagnose an SUD [APA 2013] (see Table 3: DSM-5 Diagnostic Criteria for Diagnosing and Classifying Substance 
Use Disorders, below). The DSM-5 criteria can accurately diagnose the SUD and its severity—mild, moderate, or severe—
and the assessment can be performed by the clinician or experienced staff. If expertise or resources are limited, then 
clinicians may refer the patient to a care provider who can perform the full assessment. Clinicians experienced in 
assessing and treating SUD may elect to use the DSM-5 criteria as the initial assessment tool. 
To enhance patient engagement and increase the possibility that a patient will follow through with the care plan, 
interventions must be tailored to match an individual’s perception of the problem and their readiness to change [DHHS 
1997; VA/DoD 2015; NIAAA 2016]. Based on clinical experience, the diagnostic process is an opportunity to build rapport; 
explore a patient’s attitudes toward substance use and treatment; dispel any misconceptions about treatment, 
particularly pharmacologic treatment; and engage patients in care. 
Patients often present with concurrent substance use and mental health disorders, and symptoms of one can mimic the 
other, which can complicate diagnosis and make it more challenging [SAMHSA 2019]. Clinicians should consider a 
diagnosis of SUD before establishing a primary psychiatric diagnosis (e.g., consider alcohol-induced depressive disorder 
before diagnosing a major depressive disorder). Symptoms of intoxication, such as depressed or elevated mood or 
perceptual disturbances, and symptoms of withdrawal, such as depression, anxiety, and insomnia, can also mimic 
psychiatric symptoms and should be carefully assessed. 
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Table 3: DSM-5 Diagnostic Criteria for Diagnosing and Classifying Substance Use Disorders [a,b,c] 
Criteria Type Descriptions 
Impaired control over substance 
use  
(DSM-5 criteria 1 to 4) 
• Consuming the substance in larger amounts and for a longer amount of time 
than intended. 
• Persistent desire to cut down or regulate use. The individual may have 
unsuccessfully attempted to stop in the past. 
• Spending a great deal of time obtaining, using, or recovering from the effects of 
substance use. 
• Experiencing craving, a pressing desire to use the substance. 
Social impairment  
(DSM-5 criteria 5 to 7) 
• Substance use impairs ability to fulfill major obligations at work, school, or 
home. 
• Continued use of the substance despite it causing significant social or 
interpersonal problems. 
• Reduction or discontinuation of recreational, social, or occupational activities 
because of substance use. 
Risky use  
(DSM-5 criteria 8 and 9) 
• Recurrent substance use in physically unsafe environments. 
• Persistent substance use despite knowledge that it may cause or exacerbate 
physical or psychological problems. 
Pharmacologic  
(DSM-5 criteria 10 and 11) 
• Tolerance: Individual requires increasingly higher doses of the substance to 
achieve the desired effect, or the usual dose has a reduced effect; individuals 
may build tolerance to specific symptoms at different rates. 
• Withdrawal: A collection of signs and symptoms that occurs when blood and 
tissue levels of the substance decrease. Individuals are likely to seek the 
substance to relieve symptoms. No documented withdrawal symptoms from 
hallucinogens, PCP, or inhalants. 
• Note: Individuals can have an SUD with prescription medications, so tolerance 
and withdrawal (criteria 10 and 11) in the context of appropriate medical 
treatment do not count as criteria for an SUD. 
Abbreviations: DSM-5, Diagnostic and Statistical Manual of Mental Disorders–5; PCP, phencyclidine; SUD, substance use disorder. 
Notes: 
a. Adapted from [APA 2013]. 
b. SUDs are classified as mild, moderate, or severe based on how many of the 11 criteria are fulfilled: mild, any 2 or 3 criteria; 
moderate, any 4 or 5 criteria; severe, any 6 or more criteria. 
c. Please consult the DSM-5 for substance-specific diagnostic information. 
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All Recommendations 
 All RECOMMENDATIONS 
Primary Care Screening for Adults 
• During the initial visit and during annual follow-up visits, primary care clinicians should screen for the following in 
adults ≥18 years old: 
­ Alcohol use, and when unhealthy use is identified, assess the level of risk to the patient. (A1) 
­ Tobacco use, and when it is identified, provide assessment and counseling. (A1) 
­ Drug use (B3), and when unhealthy use is identified, assess the level of risk to the patient. (A3)  
o See guideline section on Risk Assessment 
• Before screening for drug use, clinicians should explain the risks and benefits of screening to all patients, especially 
those who are pregnant or planning to conceive; the discussion should include state reporting requirements and the 
potential for involvement of child protective services. (A3) 
­ For information on the Child Abuse Prevention and Treatment Act (CAPTA) in New York State, see Plans of Safe 
Care for Infants and their Caregivers. 
• Clinicians should repeat substance use screening to inform clinical care when: 
­ Prescribing medication(s) that have adverse interactions with alcohol or drugs. (A2) 
• A patient has symptoms or medical conditions that could be caused or exacerbated by substance use. (A3) 
Screening Tools 
• Healthcare providers should use standardized and validated questionnaires for substance use screening (see Table 
1: Recommended Validated Tools for Use in Medical Settings to Screen for Alcohol and Drug Use in Adults). (A3) 
Risk Assessment 
• Clinicians should assess the level of substance use risk in individuals who have a positive substance use screening 
result or a history of substance use disorder (SUD) or overdose. (A3) 
• Clinicians should use standardized and validated tools to assess the level of risk associated with substance use (see 
Table 2: Brief, Validated Risk Assessment Tools for Use in Medical Settings With Adults ≥18 Years Old). (A3) 
Diagnosis of Substance Use Disorder 
• For accurate diagnosis of a substance use disorder (SUD) and its severity, clinicians should perform or refer patients 
for a full assessment based on Diagnostic and Statistical Manual of Mental Disorders–5 (DSM-5) criteria. (A3) 
• Clinicians should assess patients’ perceptions of their substance use and readiness to change substance use 
behaviors. (A3) 
• If individuals present with symptoms consistent with both an SUD and a mental health disorder, clinicians should 
assess for both types of disorder before making a diagnosis and should refer for specialty behavioral healthcare 
when indicated. (A3) 
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